CD274 and neoplasm: Despite multiple efforts to identify biomarkers predictive of response, such as the gene expression signatures from the IMmotion 151 trial, tumor mutational burden (TMB), and PD-L1 expression, the International mRCC Database Consortium (IMDC) risk model remains the only predictive biomarker to be prospectively validated in a phase 3 trial to date.